Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have received an average rating of “Hold” from the seven research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $62.1667.

Several equities research analysts have recently weighed in on SUPN shares. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $48.05 on Friday. Supernus Pharmaceuticals has a 1-year low of $31.35 and a 1-year high of $59.68. The stock has a market cap of $2.79 billion, a P/E ratio of -94.22, a P/E/G ratio of 1.03 and a beta of 0.54. The firm has a fifty day moving average price of $47.18 and a 200 day moving average price of $49.50.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. Rockefeller Capital Management L.P. increased its stake in Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 660 shares during the period. Torren Management LLC purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at about $49,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $51,000. Hantz Financial Services Inc. increased its stake in shares of Supernus Pharmaceuticals by 73.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 458 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth about $55,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.